Versant Capital Management’s OptimizeRx OPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$8.86K Hold
1,061
– – ﹤0.01% 2301
2026
Q2
$6.07K Sell
1,061
-980
-48% -$5.63K ﹤0.01% 2388
2026
Q1
$12.8K Buy
2,041
+248
+14% +$2.3K ﹤0.01% 2029
2025
Q4
$22K Hold
1,793
– – ﹤0.01% 1578
2025
Q3
$36.8K Hold
1,793
– – 0.01% 1213
2025
Q2
$24.2K Hold
1,793
– – ﹤0.01% 1413
2025
Q1
$15.5K Buy
1,793
+1,559
+666% +$9.5K ﹤0.01% 1479
2024
Q4
$1.14K Buy
+234
New +$1.31K ﹤0.01% 2165

Other funds holding OPRX

Versant Capital Management's OPRX Position: Q3 2026 in Review

Versant Capital Management held its OptimizeRx (OPRX) position steady in Q3 2026 at 1,061 shares worth $8.86K. The position accounts for ﹤0.01% of the portfolio, ranked #2301.

Versant Capital Management first reported a position in OPRX in Q4 2024 and has held it in 8 quarters since. The position peaked at $36.8K in Q3 2025. 103 funds tracked by Wall St. Rank hold OPRX as of Q3 2026.

  • Versant Capital Management held 1,061 shares of OptimizeRx worth $8.86K as of Q3 2026.
  • Versant Capital Management left its OptimizeRx share count unchanged in Q3 2026.
  • OptimizeRx made up ﹤0.01% of Versant Capital Management's portfolio in Q3 2026, its #2301 holding.
  • Versant Capital Management first reported a position in OptimizeRx in Q4 2024 and has held it in 8 quarters since.
  • Versant Capital Management's OptimizeRx position peaked at $36.8K in Q3 2025.
  • 103 funds tracked by Wall St. Rank held OptimizeRx as of Q3 2026.

Based on Versant Capital Management's 13F filing for Q3 2026, filed 2 Oct 2026.